These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 16316890

  • 1. Therapeutic efficacy of infliximab on active Crohn's disease under nutritional therapy.
    Matsumoto T, Iida M, Kohgo Y, Imamura A, Kusugami K, Nakano H, Fujiyama Y, Matsu T, Hibi T.
    Scand J Gastroenterol; 2005 Dec; 40(12):1423-30. PubMed ID: 16316890
    [Abstract] [Full Text] [Related]

  • 2. Therapeutic efficacy of infliximab on patients with short duration of Crohn's disease: a Japanese multicenter survey.
    Matsumoto T, Iida M, Motoya S, Haruma K, Suzuki Y, Kobayashi K, Ito H, Miyata M, Kusunoki M, Chiba T, Yamamoto S, Hibi T.
    Dis Colon Rectum; 2008 Jun; 51(6):916-23. PubMed ID: 18322754
    [Abstract] [Full Text] [Related]

  • 3. [Therapeutic effects of combined enteral nutrition with Tripterygium Wilfordii poly-glycoside in remission induction of active adult Crohn's disease].
    Gong JF, Niu LY, Wei XW, Zhu WM, Li N, Li JS.
    Zhonghua Wai Ke Za Zhi; 2009 Aug 15; 47(16):1213-7. PubMed ID: 19781164
    [Abstract] [Full Text] [Related]

  • 4. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
    Hyder SA, Travis SP, Jewell DP, McC Mortensen NJ, George BD.
    Dis Colon Rectum; 2006 Dec 15; 49(12):1837-41. PubMed ID: 17041753
    [Abstract] [Full Text] [Related]

  • 5. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR, Ficari F, Bagnoli S, Milla M, Tonelli F.
    Scand J Gastroenterol; 2006 Sep 15; 41(9):1064-72. PubMed ID: 16938720
    [Abstract] [Full Text] [Related]

  • 6. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R, REACH Study Group.
    Gastroenterology; 2007 Mar 15; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [Abstract] [Full Text] [Related]

  • 7. Factors affecting recurrence in patients with Crohn's disease under nutritional therapy.
    Esaki M, Matsumoto T, Nakamura S, Yada S, Fujisawa K, Jo Y, Iida M.
    Dis Colon Rectum; 2006 Oct 15; 49(10 Suppl):S68-74. PubMed ID: 17106818
    [Abstract] [Full Text] [Related]

  • 8. Clinical advantages of combined seton placement and infliximab maintenance therapy for perianal fistulizing Crohn's disease: when and how were the seton drains removed?
    Tanaka S, Matsuo K, Sasaki T, Nakano M, Sakai K, Beppu R, Yamashita Y, Maeda K, Aoyagi K.
    Hepatogastroenterology; 2010 Oct 15; 57(97):3-7. PubMed ID: 20422862
    [Abstract] [Full Text] [Related]

  • 9. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease.
    Berni Canani R, Terrin G, Borrelli O, Romano MT, Manguso F, Coruzzo A, D'Armiento F, Romeo EF, Cucchiara S.
    Dig Liver Dis; 2006 Jun 15; 38(6):381-7. PubMed ID: 16301010
    [Abstract] [Full Text] [Related]

  • 10. The effects of infliximab maintenance therapy on health-related quality of life.
    Feagan BG, Yan S, Bala M, Bao W, Lichtenstein GR.
    Am J Gastroenterol; 2003 Oct 15; 98(10):2232-8. PubMed ID: 14572573
    [Abstract] [Full Text] [Related]

  • 11. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease.
    Baldassano R, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan GF, Winter HS.
    Am J Gastroenterol; 2003 Apr 15; 98(4):833-8. PubMed ID: 12738464
    [Abstract] [Full Text] [Related]

  • 12. Infliximab treatment for symptomatic Crohn's disease strictures.
    Pelletier AL, Kalisazan B, Wienckiewicz J, Bouarioua N, Soulé JC.
    Aliment Pharmacol Ther; 2009 Feb 01; 29(3):279-85. PubMed ID: 19035967
    [Abstract] [Full Text] [Related]

  • 13. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas?
    Gaertner WB, Decanini A, Mellgren A, Lowry AC, Goldberg SM, Madoff RD, Spencer MP.
    Dis Colon Rectum; 2007 Nov 01; 50(11):1754-60. PubMed ID: 17899271
    [Abstract] [Full Text] [Related]

  • 14. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
    Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, Patel K, Wolf DC, Safdi M, Colombel JF, Lashner B, Hanauer SB.
    Gastrointest Endosc; 2006 Mar 01; 63(3):433-42; quiz 464. PubMed ID: 16500392
    [Abstract] [Full Text] [Related]

  • 15. Effect of concurrent elemental diet on infliximab treatment for Crohn's disease.
    Tanaka T, Takahama K, Kimura T, Mizuno T, Nagasaka M, Iwata K, Nakano H, Muramatsu M, Takazoe M.
    J Gastroenterol Hepatol; 2006 Jul 01; 21(7):1143-9. PubMed ID: 16824066
    [Abstract] [Full Text] [Related]

  • 16. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.
    Gisbert JP, Panés J.
    Am J Gastroenterol; 2009 Mar 01; 104(3):760-7. PubMed ID: 19174781
    [Abstract] [Full Text] [Related]

  • 17. [A comparative study of induction of remission and cost-effectiveness of enteral nutrition versus infliximab in moderate-to-severe Crohn's disease].
    Zhu WM, Zuo LG, Li Y, Cao L, Zhang W, Gu YF, Xu M, Li N, Li JS.
    Zhonghua Nei Ke Za Zhi; 2013 Sep 01; 52(9):721-5. PubMed ID: 24314158
    [Abstract] [Full Text] [Related]

  • 18. Concomitant use of enteral nutrition therapy is associated with sustained response to infliximab in patients with Crohn's disease.
    Sazuka S, Katsuno T, Nakagawa T, Saito M, Saito K, Matsumura T, Arai M, Sato T, Yokosuka O.
    Eur J Clin Nutr; 2012 Nov 01; 66(11):1219-23. PubMed ID: 23010687
    [Abstract] [Full Text] [Related]

  • 19. Low-dose naltrexone therapy improves active Crohn's disease.
    Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS.
    Am J Gastroenterol; 2007 Apr 01; 102(4):820-8. PubMed ID: 17222320
    [Abstract] [Full Text] [Related]

  • 20. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
    Hlavaty T, Pierik M, Henckaerts L, Ferrante M, Joossens S, van Schuerbeek N, Noman M, Rutgeerts P, Vermeire S.
    Aliment Pharmacol Ther; 2005 Oct 01; 22(7):613-26. PubMed ID: 16181301
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.